Compare Royal Bank of Canada (RY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs Spyre Therapeutics Inc. Common Stock — how do they compare? Royal Bank of Canada trades at $193.47 (market cap $268.76B), while Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B). The key difference: Royal Bank of Canada is far larger — about 36.6× Spyre Therapeutics Inc. Common Stock's market cap, and Royal Bank of Canada pays a 2.62% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royal Bank of Canada for 48 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| RY | SYRE | |
|---|---|---|
Market Cap | $268.76B | $7.35B |
Volume | 726,877 | 1,624,631 |
Sector | Financials | Health |
52-Week High | $217.87 | $108.92 |
52-Week Low | $145.31 | $22.18 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $737.27B | $6.35B |
Dividend Yield | 2.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $194.67, up 0.99% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.07 exceeding expectations. Revenue grew to $66.53B in 2025, and net income margin improved to 32.01%. Recent news highlights record Q3 2026 results and strategic initiatives like the unified Global Transaction Banking business.
Outlook remains positive with projected 2026 revenue of $71.1B and net income of $22.7B, though stretched valuations and technical bearishness pose risks. Analyst consensus is mixed with 43% buy ratings, but institutional buying activity supports confidence. Key risks include macroeconomic sensitivity and competitive pressures in the banking sector.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
